Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127565721 | 12756572 | 1 | I | 20160906 | 20160917 | 20160917 | EXP | BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-124122 | RANBAXY | 36.00 | YR | M | Y | 0.00000 | 20160917 | OT | GB | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127565721 | 12756572 | 1 | PS | PREDNISONE. | PREDNISONE | 1 | Oral | U | U | 89247 | 1 | MG/KG | |||||||
| 127565721 | 12756572 | 2 | SS | Doxorubicin | DOXORUBICIN | 1 | Unknown | Q21 DAYS; 3 CYCLES | U | U | 0 | 60 | MG/M**2 | ||||||
| 127565721 | 12756572 | 3 | SS | INTERFERON ALFA NOS | INTERFERON ALFA-2A OR INTERFERON ALFA-2B | 1 | Unknown | U | U | 0 | 3000000 | IU | TIW | ||||||
| 127565721 | 12756572 | 4 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 1 CYCLE | U | U | 0 | 1000 | MG/M**2 | ||||||
| 127565721 | 12756572 | 5 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | DIVIDED IN 5 DOSES Q21 DAYS; 3 CYCLES | U | U | 0 | 9000 | MG/M**2 | ||||||
| 127565721 | 12756572 | 6 | C | PACLITAXEL. | PACLITAXEL | 1 | Unknown | WEEKLY; 8 CYCLES | U | 0 | 80 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127565721 | 12756572 | 1 | Intravascular papillary endothelial hyperplasia |
| 127565721 | 12756572 | 2 | Intravascular papillary endothelial hyperplasia |
| 127565721 | 12756572 | 3 | Intravascular papillary endothelial hyperplasia |
| 127565721 | 12756572 | 4 | Intravascular papillary endothelial hyperplasia |
| 127565721 | 12756572 | 5 | Intravascular papillary endothelial hyperplasia |
| 127565721 | 12756572 | 6 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127565721 | 12756572 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127565721 | 12756572 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127565721 | 12756572 | 1 | 2014 | 0 | ||
| 127565721 | 12756572 | 2 | 2015 | 0 | ||
| 127565721 | 12756572 | 3 | 2015 | 0 | ||
| 127565721 | 12756572 | 4 | 2015 | 0 | ||
| 127565721 | 12756572 | 5 | 2015 | 0 | ||
| 127565721 | 12756572 | 6 | 2014 | 201410 | 0 |